Loading...
XSTO
IZAFE B
Market cap12mUSD
Oct 09, Last price  
0.29SEK
1D
-3.06%
1Q
-25.00%
Jan 2017
-96.39%
IPO
-89.44%
Name

iZafe Group AB

Chart & performance

D1W1MN
XSTO:IZAFE B chart
P/E
—
P/S
19.31
EPS
—
Div yield, %
—
Shrs. gr., 5y
57.40%
Rev. gr., 5y
-7.62%
Revenues
6m
-24.68%
3,75026,41939,1015,698000155,0007,571,00014,328,0008,904,000442,000729,0001,822,0007,954,0005,991,000
Net income
-17m
L-18.69%
-5,907,245-4,941,580-2,917,935-7,228,886-3,170,867-2,596,712-6,356,026-4,269,000-11,312,000-23,116,000-12,754,000-36,275,000-23,526,000-32,175,000-20,509,000-16,675,999
CFO
-15m
L+28.21%
-1,621,933-941,317-829,552-1,772,786-4,316,036-3,719,000-1,410,000-15,319,000-24,567,000-33,493,000-21,457,000-11,256,000-11,355,000-14,558,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

iZafe Group AB (publ), a medical technology company, engages in the research, development, and marketing of digital medical solutions and services for safer drug management at home. The company provides Dosell, an automated medication dispenser that handles medication pouches, smart pillboxes, facilitates and enables independent medication, and reminds and alerts in the scheduled doses. It also offers Pilloxa, a platform that provides real-time insights and improved data quality to empower and motivate patients. The company was formerly known as MediRätt AB (publ) and changed its name to iZafe Group AB (publ) in May 2019. iZafe Group AB (publ) was incorporated in 2008 and is headquartered in Stockholm, Sweden.

Key people

Anders Segerstrom
Chief Executive Officer · since 2019
Tobias Johansson
Deputy Chief Executive Officer, Director of Sales · since 2019
Thomas Ahlerup
Acting Chairman of the Board · since 2019
Viveca Gyberg
Director · since 2018
Goran Hermanson
Chief Operating Officer, Director · since 2019
IPO date
Apr 04, 2011
Employees
Domiciled in
SE
Incorporated in
SE
Headquarters & legal address
David bagares gata 3 BV
STOCKHOLM, AB 111 38
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT